Redcliffe Lifetech raises $61 million in Series B

According to Dheeraj Jain, founder of Redcliffe Lifetech, preventative medicine aims to empower the common Indians with the information they need to take care of their health and welfare. "Redcliffe has created a one-stop diagnostic shop, offering a wide range of tests and bringing treatment closer to the client." This investment will help us scale

Redcliffe Life Sciences, located in New Delhi, announced a *$61 million funding round led by LeapFrog Investments on Friday (LeapFrog).

Other investors in the round included Healthquad, Schroders, LC Nueva, and Growth Spark Ventures, as well as current investors Chiratae Ventures and Alkemi Venture Partners.

The startup raised $10 million in its Series A fundraising round last year.

The diagnostic platform will utilize the funding to extend its low-cost but high-quality direct-to-consumer diagnostics into Tier-II, III, and IV cities, providing affordable, speedy, and accessible pathology services to millions of households.

According to Dheeraj Jain, founder of Redcliffe Lifetech, preventative medicine aims to empower the common Indians with the information they need to take care of their health and welfare. "Redcliffe has created a one-stop diagnostic shop, offering a wide range of tests and bringing treatment closer to the client." This investment will help us scale to fulfil our aim of reaching over 500 million Indians in the next five years,"

Redcliffe will also use the funds to extend its platform and expand its product offerings including radiography, illness data profiling, and lifestyle management in an attempt to reform India's healthcare focus from treatment to early diagnosis and prevention.

Across 14 cities, Redcliffe Diagnostics operates 22 state-of-the-art labs.

Its unique omnichannel infrastructure — which combines an online channel with a fleet of 400 phlebotomists operating in 100+ cities with home sample collection and an offline network of 500 collection centers — enables the company to offer over 3,500 different pathology and highly specialized tests, including genetics at affordable prices around 25-60 percent less than traditional competitors.

The company's current annualized sales run rate, according to Jain, is approximate $55- $60 million.
Redcliffe's low-cost diagnostics are intended to help reduce the burden of noncommunicable diseases (NCDs), such as heart disease, cancer, and diabetes, which harm over six million Indians each year.

Tags : #fundingalert #funding #investments #investors #redcliffe #diagnostics #indianstartups #startupfunding #healthcare #healthcarestartups #dheerajjain #smitakumar #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024